Download PDF
Semin Thromb Hemost 2010; 36(8): 797-802
DOI: 10.1055/s-0030-1267031
EDITORIAL

© Thieme Medical Publishers

Farewell to 2010!

Emmanuel J. Favaloro1
  • 1Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, SWAHS, Westmead, NSW, Australia
Further Information

Publication History

Publication Date:
03 November 2010 (online)

    Permissions and Reprints

Welcome to the end of another year of Seminars in Thrombosis and Hemostasis, the second year with a restructured and expanded editorial team, including yours truly as editor in chief. We have already described the events that led to the formation of the new team, including the passing of the journal's founding editor in chief, Eberhard F. Mammen, in 2008.[1] [2] [3] [4] [5] [6] [7] [8]

I would like to thank our entire editorial team, our guest editors, and all the authors who have contributed articles for their respective contributions to the journal over the past year. I would also like to thank all the members of the Thieme team, whose contribution to the success is critical but generally goes unrecognized by the readership. In particular, I would like to acknowledge the invaluable assistance of Xenia Golovchenko, a production editor for Thieme Medical Publishers, who is ultimately responsible for bringing every issue of Seminars in Thrombosis and Hemostasis to press.

I would also take this time to comment on the journal's impact factor, which for 2009 was 3.214 (Fig. [1]). Although this reflects a drop from our 2008 impact factor, it can largely be explained by the delayed publication of many of the issues we produced in 2007 and 2008, reflecting the difficult period related to the protracted illness and eventual death of Eberhard Mammen. In fact, the impact factor for 2009 is similar to that of 2007, suggesting that Seminars in Thrombosis and Hemostasis is still well and truly on the right path. The impact factor is not the only marker of journal quality we should consider, however.[9] [10] The top 45 list of 2009-cited (2007/2008-published) articles appears in Table [1].[9] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] These articles were identified as those contributing the most to the 2009 impact factor, and each was cited five or more times in 2009.

Figure 1 Seminars in Thrombosis and Hemostasis impact factor for 2003 to 2009.

Table 1 Top 45 Listing of 2009-Cited Articles from This Journal, Published in 2007 or 2008* Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost 2007;33(8):771–779 Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007;33(3):273–282 Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007;33(8):727–744 Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007;33(5):515–523 Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008;34(3):236–250 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33(4):313–320 Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost 2007;33(7):712–721 Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost 2007;33(6):573–581. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34(1):58–73 Ferro V, Dredge K, Liu L, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007;33(5):557–568 Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32(8):803–809 Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34(1):39–57 Watson HG, Greaves M. Can we predict bleeding? Semin Thromb Hemost 2008;34(1):97–103. Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 2007;33(4):321–329 Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008;34(1):104–112 Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007;33(5):478–487. Borsig L. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost 2007;33(5):540–546 Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008;34(2):204–210 Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008;34(1):7–25 Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008;34(1):128–141 Lippi G, Franchini M, Montagnana M, Guidi GC. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. Semin Thromb Hemost 2007;33(8):759–770 Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 2007;33(6):563–572 Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 2008;34(3):267–273 Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007;33(4):339–349 Zwicker JI. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008;34(2):195–198 Asherson RA. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost 2008;34(3):227–235 Favaloro EJ, Wong RC. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 2008;34(4):389–410 Milsom C, Yu J, May L, Magnus N, Rak J. Diverse roles of tissue factor-expressing cell subsets in tumor progression. Semin Thromb Hemost 2008;34(2):170–181 Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008;34(1):86–96 Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007;33(7):653–659 Tsopanoglou NE, Maragoudakis ME. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1. Semin Thromb Hemost 2007;33(7):680–687 Wong RC, Favaloro EJ. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost 2008;34(3):295–304 Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007;33(4):350–354 Cunningham MT, Brandt JT, Chandler WL, et al. Quality assurance in hemostasis: the perspective from the College of American Pathologists proficiency testing program. Semin Thromb Hemost 2007;33(3):250–258 de Lamirande E. Semenogelin, the main protein of the human semen coagulum, regulates sperm function. Semin Thromb Hemost 2007;33(1):60–68 Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008;34(3):290–294 Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007;33(7):688–694 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008;34(1):113–127 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007;33(8):787–797 Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost 2007;33(4):373–388 Linhardt RJ, Dordick JS, Deangelis PL, Liu J. Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost 2007;33(5):453–465 Lockwood CJ, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F. The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin Thromb Hemost 2007;33(1):111–117 Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007;33(5):524–533 Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 2008;34(2):154–160 Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008;34(2):147–153 Each of these articles were cited between 5 and 13 times in 2009. These would therefore be identified as most contributing to the 2009 impact factor for Seminars in Thrombosis and Hemostasis. The articles are listed in decreasing order of citations or alphabetically for those articles having the same number of citations.

The same editorial team will be staying with Seminars in Thrombosis and Hemostasis next year to bring you the high-quality journal you have come to expect. Table [2] lists the topics currently confirmed for upcoming issues. We will add additional material of current interest and controversy as the need arises.

Table 2 Current Planned Topics for Future Issues of Seminars in Thrombosis and Hemostasis • Hormones, endocrine disorders, and hemostasis • Forgotten factors in thrombosis and hemostasis • Von Willebrand disease • Mechanisms of inherited and acquired thrombocytopenia • Pediatric Issues in hemostasis and thrombosis • Key molecules in thrombosis and hemostasis • Cerebrovascular thrombosis and hemostasis • Laboratory and clinical identification and treatment of bleeding disorders • Autoimmunity and hemostasis: thrombotic and hemorrhagic syndromes • Quality in thrombosis and hemostasis

We all look forward to another interesting year of reading in 2011!

REFERENCES

Emmanuel J FavaloroPh.D. M.A.I.M.S. 

Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR)

Westmead Hospital, WSAHS, Westmead, NSW 2145, Australia

Email: emmanuel.favaloro@swahs.health.nsw.gov.au

      >